VIVS logo

VivoSim Labs, Inc.

VIVS
Healthcare|Biotechnology|US
$0.14
+0.00 (+0.07%)
DCF Value
$1.67
Cash / Share
$0.32
Next Earnings Report
Feb 9, 2027
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Jul 31, 2026 (S-1). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
Nov 3, 2026 · GlobeNewsWire
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
Oct 21, 2026 · GlobeNewsWire
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
Oct 7, 2026 · GlobeNewsWire
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
Sep 16, 2026 · GlobeNewsWire
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
Sep 1, 2026 · GlobeNewsWire

SEC Filings (16)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 16, 20268-KMaterial eventDocumentIndex
Oct 6, 20268-KMaterial eventDocumentIndex
Aug 21, 2026ARSAnnual report to holdersDocumentIndex
Aug 21, 20268-KMaterial eventDocumentIndex
Aug 21, 2026DEF 14AProxy / shareholder voteDocumentIndex
Aug 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 2026PRER14ADocumentIndex
Aug 12, 202610-QQuarterly reportDocumentIndex
Aug 10, 2026EFFECTDocumentIndex
Aug 10, 2026PRE 14AProxy / shareholder voteDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 31, 2026S-1IPO / offering registrationDocumentIndex
Jul 30, 20268-KMaterial eventDocumentIndex
Jul 24, 20268-KMaterial eventDocumentIndex
Jul 17, 20268-KMaterial eventDocumentIndex
Jul 14, 202610-KAnnual reportDocumentIndex